Osimertinib was approved as a first‐line treatment for lung cancer with EGFR mutations in 2018, and therefore tarloxotinib may be a suitable second‐line EGFR‐TKI for lung cancers with exon 19 deletions or with L858R point mutation. The gene discussed is EGFR; the disease is lung carcinoma.